- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy ; volume:23 ; number:1 ; day:8 ; month:5 ; year:2023 ; pages:1-22 ; date:12.2023
Cancer cell international ; 23, Heft 1 (8.5.2023), 1-22, 12.2023
- Urheber
-
Hadiloo, Kaveh
Tahmasebi, Safa
Esmaeilzadeh, Abdolreza
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-023-02923-9
- URN
-
urn:nbn:de:101:1-2023090708233882071530
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
2025-08-14T10:50:34+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hadiloo, Kaveh
- Tahmasebi, Safa
- Esmaeilzadeh, Abdolreza
- SpringerLink (Online service)
Ähnliche Objekte (12)
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Outsmarting trogocytosis to boost CAR NK/T cell therapy
"PuNKt"
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
Natural killer cells: a promising immunotherapy for cancer
An overview of PROTACs: a promising drug discovery paradigm
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm
New Paradigm in NKT Cell Antigens: MCS‐0208 (2‐(Hydroxymethyl)phenylthio‐phytoceramide) – an Aryl‐Phytoceramide Compound with a Single Hydroxyl Group Stimulates NKT Cells
New cell sources for CAR-based immunotherapy